Drug Profile

Research programme: cardiovascular disorders therapeutics - Eli Lilly and Company/Verve Therapeutics

Alternative Names: in vivo gene editing therapies targeting Lp(a) - Eli Lilly and Company/Verve Therapeutics

Latest Information Update: 05 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

25 Jul 2025 Verve Therapeutics has been acquired by Eli Lilly and Company
15 Jun 2023 Verve Therapeutics and Eli Lilly and Company enters into a research collaboration with Eli Lilly and Company focused on in vivo gene editing program targeting lipoprotein(a)
15 Jun 2023 Early research in Cardiovascular disorders in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com